Qiagen Forecast, price target & analysts
Qiagen Target price 2025 - Analyst rating & recommendation
Qiagen Classifications & Recommendation:
Qiagen Price Target
| Target Price | €43.89 |
| Price | €40.13 |
| Potential | 9.36% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €43.89. This is 9.36% higher than the current stock price. The highest price target is €50.00 24.60% , the lowest is €39.08 2.62% . | |
| A rating was issued by 22 analysts: 12 Analysts recommend Qiagen to buy, 10 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 9.36% . Most analysts recommend the Qiagen stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
17 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 7.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 9.27% , the lowest is €1.8b 4.60% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €1.7b | 0.66% |
|---|---|---|
| 2025 | €1.8b | 7.28% |
| 2026 | €1.9b | 5.99% |
| 2027 | €2.1b | 6.97% |
| 2028 | €2.2b | 7.21% |
| 2029 | €2.4b | 8.20% |
16 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €678m . This is 56.67% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €754m 74.15% , the lowest is €620m 43.29% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €433m | 10.64% |
|---|---|---|
| 2025 | €678m | 56.67% |
| 2026 | €732m | 7.93% |
| 2027 | €792m | 8.27% |
| 2028 | €845m | 6.63% |
| 2029 | €922m | 9.05% |
EBITDA Margin
| 2024 | 25.51% | 9.92% |
|---|---|---|
| 2025 | 37.25% | 46.05% |
| 2026 | 37.93% | 1.83% |
| 2027 | 38.39% | 1.21% |
| 2028 | 38.18% | 0.55% |
| 2029 | 38.48% | 0.79% |
10 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €391m . This is 444.75% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €448m 525.17% , the lowest is €333m 365.00% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €71.7m | 75.51% |
|---|---|---|
| 2025 | €391m | 444.75% |
| 2026 | €434m | 11.22% |
| 2027 | €486m | 11.83% |
| 2028 | €531m | 9.34% |
| 2029 | €571m | 7.40% |
Net Margin
| 2024 | 4.23% | 75.67% |
|---|---|---|
| 2025 | 21.46% | 407.88% |
| 2026 | 22.51% | 4.89% |
| 2027 | 23.54% | 4.58% |
| 2028 | 24.00% | 1.95% |
| 2029 | 23.83% | 0.71% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
10 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €1.81 . This is 483.87% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.07 567.74% , the lowest is €1.54 396.77% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €0.33 | 74.81% |
|---|---|---|
| 2025 | €1.81 | 448.48% |
| 2026 | €2.01 | 11.05% |
| 2027 | €2.25 | 11.94% |
| 2028 | €2.46 | 9.33% |
| 2029 | €2.64 | 7.32% |
P/E ratio
| Current | 129.45 | 337.48% |
|---|---|---|
| 2025 | 22.20 | 82.85% |
| 2026 | 19.96 | 10.09% |
| 2027 | 17.85 | 10.57% |
| 2028 | 16.33 | 8.52% |
| 2029 | 15.20 | 6.92% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.95 and an P/S ratio of 4.84 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 5.31 | 1.85% |
|---|---|---|
| 2025 | 4.95 | 6.70% |
| 2026 | 4.67 | 5.65% |
| 2027 | 4.37 | 6.52% |
| 2028 | 4.08 | 6.73% |
| 2029 | 3.77 | 7.58% |
P/S ratio
| Current | 5.19 | 1.98% |
|---|---|---|
| 2025 | 4.84 | 6.78% |
| 2026 | 4.57 | 5.65% |
| 2027 | 4.27 | 6.52% |
| 2028 | 3.98 | 6.73% |
| 2029 | 3.68 | 7.58% |
Current Qiagen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
| Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
| Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
| Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
| Morgan Stanley |
Overweight
➜
Equal-Weight
|
Downgrade | Jan 06 2025 |
| HSBC |
Buy
➜
Hold
|
Downgrade | Oct 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
|
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
|
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
|
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
|
Downgrade
Morgan Stanley:
Overweight
➜
Equal-Weight
|
Jan 06 2025 |
|
Downgrade
HSBC:
Buy
➜
Hold
|
Oct 17 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
